+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID07267234

Combination of PRaG-1 Cordycepin Tablets with Radiotherapy, GM-CSF, and PD-1PD-L1 Inhibitors for Elderly Patients with Advanced Solid Tumors

Led by Second Affiliated Hospital of Soochow University · Updated on 2026-10-27

65

Participants Needed

1

Research Sites

39 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating whether a combination treatment using PRaG-1 Cordycepin Tablets along with radiation therapy, immune-boosting injections, and immunotherapy drugs can help patients with advanced solid tumors. This phase 2 clinical trial also aims to assess the safety of this combination and its effects on immune function and tumor growth in elderly patients. The study is sponsored by the Second Affiliated Hospital of Soochow University and focuses on patients 65 years or older with advanced solid cancers and low lymphocyte counts. Participants will take PRaG-1 Cordycepin Tablets orally, starting with a higher dose for 7 days before radiation therapy, followed by a lower daily dose for 2 weeks per cycle. Radiation therapy is delivered in 2 to 3 sessions targeting tumor sites. Daily immune-boosting injections of GM-CSF are given for 7 days starting with radiation, and immunotherapy drugs PD-1PD-L1 inhibitors begin within one week after radiation. Treatment phases include at least two cycles of combination therapy, followed by maintenance therapy with immunotherapy, GM-CSF, and cordycepin for six months or until disease progression or unacceptable side effects. Participants will undergo blood draws and small tumor biopsies before and after the first two treatment cycles to analyze immune changes. Immune function is studied through detailed laboratory tests including RNA sequencing and proteomic analyses. Researchers will monitor tumor response, disease control, progression-free survival, and any adverse events over 36 months. The study includes continuous safety monitoring and allows for treatment discontinuation based on disease progression, toxicity, or participant choice.

CONDITIONS

Brief Title

PRaG-1 Plus PRaG Therapy in in Elderly Patients With Advanced Solid Tumors: A Prospective Clinical Trial (PRaG 10.0)

Research Team

L

Liyuan Zhang, Doctor

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here